Showing 2321-2330 of 3017 results for "".
- CMS Updates Quality Reporting Requirements in Light of COVID-19https://practicaldermatology.com/news/cms-updates-quality-reporting-requirements/2460315/CMS is granting exceptions from reporting requirements and extensions for clinicians and providers participating in Medicare quality reporting programs with respect to upcoming measure reporting and data submission for those programs. For those programs with data submission deadl
- AAD Offers Tips for Practicing in the Era of COVID-19https://practicaldermatology.com/news/aad-offers-tips-for-practicing-in-the-era-of-covid-19/2460313/The American Academy of Dermatology released new guidance for dermatologists amid the COVID-19 crisis including an update on teledermatology and reimbursement codes. The guidance includes: March 19th AAD President’s Message:
- Dermatologist Urges Vigilance for Exanthem as Coronavirus Spreadshttps://practicaldermatology.com/news/dermatologist-urges-vigilance-for-exanthem-as-coronavirus-spreads/2460304/As the novel coronavirus spreads across the US and the World Health Organization declares a global pandemic, dermatologists may be able to play a role in diagnosing and combating the disease, says New York City dermatologist Bobby Buka, MD, JD. In fact, the cofounder of The Dermatology Specialist
- Sciton Names New CEOhttps://practicaldermatology.com/news/sciton-names-new-ceo/2460292/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently operations in our World Head
- Acne Pipeline Watch: Dermata Therapeutics Completes Enrollment in Phase 2b Trial of Once-Weekly Topical DMT310 for Acnehttps://practicaldermatology.com/news/acne-pipeline-watch-dermata-therapeutics-completes-enrollment-in-phase-2b-trial-of-once-weekly-topical-dmt310-for-acne/2460282/Dermata Therapeutics, LLC completed enrollment of patients in its Phase 2b clinical trial evaluating the safety, tolerability and efficacy of DMT310 in moderate to severe acne patients. The Phase 2b trial enrolled 182 patients randomly in two group
- Revance: FDA Accepts BLA for DaxibotulinumtoxinA, Sets November PDUFA Datehttps://practicaldermatology.com/news/revance-fda-accepts-bla-for-daxibotulinumtoxina-sets-november-pdufa-date/2460278/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Aerolase and Eucerin Join Forces to Optimize Patient Outcomes in Laser Treatmentshttps://practicaldermatology.com/news/aerolase-and-eucerin-join-forces-to-optimize-patient-outcomes-in-laser-treatments-1/2460277/Aerolase and Eucerin are working together to optimize laser treatment protocols in the D-A-CH-region (Germany-Austria-Switzerland). Furthermore, both companies will develop therapies for adjunctive care post-laser treatments. Both companies will also conduct a joint symposium
- Derms Still Need Disaster Preparedness Traininghttps://practicaldermatology.com/news/derms-still-need-disaster-preparedness-training/2460271/The dermatology community is inadequately prepared for a biological disaster and would benefit from a formal preparedness training program, according to a study from the George Washington University (GW) that appears in the Jour
- Mattel Releases New Barbie Dolls with Vitiligo, Alopeciahttps://practicaldermatology.com/news/mattel-releases-new-barbie-dolls-with-vitiligo-alopecia-1/2460268/In an effort to be more inclusive, Mattel, the maker of Barbie dolls, has released new dolls in its Fashionista line including a Barbie with alopecia and one with vitiligo. “For 2020, Barbie is continuing the journey to represent global diversity and inclusivity in the f
- Cynosure Taps Todd Tillemans As New CEOhttps://practicaldermatology.com/news/cynosure-taps-todd-tillemans-as-new-ceo-2/2460262/Todd Tillemans is the new Chief Executive Officer of Cynosure, LLC. Mr. Tillemans is the former President of Hershey's flagship U.S. business generating more than $6.5 billion in annual sales. Prior to that, he held various leadership positions across Unilever's